Concurrent Sessions

3:30 – 4:30 pm Thursday, October 28

Administration and Management of Anti-GD2 Immunotherapy for High Risk Neuroblastoma in the Outpatient Setting (200)

Neuroblastoma, the most common extracranial solid tumor in children, develops from neural crest cells that, typically, differentiate to form the sympathetic nervous system. Most neuroblastoma cases present as high-risk neuroblastoma, which has long been associated with high relapse rates and poor survival.

Read more...
3:30 – 4:30 pm Thursday, October 28

Joint Topic: Error Prevention — Decreasing CLABSI through inter-specialty nurse rounding (201-1)

Central lines are integral in the delivery of chemotherapy and supportive care for pediatric oncology patients. However, central lines are associated with increased morbidity and mortality, especially in immunocompromised children. After a spike in central line–associated bloodstream infections (CLABSIs) in our hospital, our harm prevention department required weekly checks of every central line.

Read more...
3:30 – 4:30 pm Thursday, October 28

Joint Topic: Error Prevention — Tier Zero: Preventing Harm Before it Happens (201-2)

The care of the pediatric patient with cancer is complex. Patients are at increased risk of harm from falls, central line infections, thrombosis, and pressure injuries resulting from the treatment they receive. The Harm Prevention Program at our organization provides a structure and processes for identifying and reviewing patient harm events.

Read more...
3:30 – 4:30 p, Thursday, October 28

The Impact of a Global Pandemic on Pediatric Hematology Oncology Nurses, Patients, and Families (203)

Since it was first discovered in Wuhan, China, in December 2019, the SARS-CoV-2 virus has reached nearly every country in the world, causing a once-in-a-lifetime pandemic that has placed undue stress on healthcare providers globally.

Read more...
5:00 – 6:00 pm Thursday, October 28

“It’s my Body!”: Engaging Children and Adolescents Through Goals of Care Discussions on End of Life (206)

Childhood and adolescence are a time to navigate autonomy, yet our medical system looks to parents to make “official” decisions until children are 18 years old. The American Academy of Pediatrics recommends children and adolescents with life-limiting illnesses be provided an opportunity to participate in decisions affecting their care in a developmentally appropriate manner.

Read more...
5:00 – 6:00 pm Thursday, October 28

Joint Topic: Advanced Practice Provider Postgraduate Training Programs — Developing an Advanced Practice Provider Postgraduate Training Program for Pediatric Oncology Programs (207-1)

Advanced practice providers (APPs) are fundamental members of the pediatric oncology team, often acting as a continuous presence during the child’s treatment journey. With the rapid pace of treatment advances and an increase in the acuity of pediatric oncology patients, we know that generalized pediatric training does not adequately prepare us to care for children with cancer.

Read more...
5:00 – 6:00 pm Thursday, October 28

Joint Topic: Advanced Practice Provider Postgraduate Training Programs — Advanced Practice Provider Fellowships: The Path to Specialized Excellence (207-2)

The role of the advanced practice provider (APP) has been expanding for decades and is now essential in most healthcare organizations. The majority of APP programs are population-specific (e.g., pediatric, family, adult, geriatric), with very few programs that are specialized beyond primary versus acute care.

Read more...